• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)核蛋白在新出现变异株背景下的诊断和疫苗接种中的作用:现状与展望

The role of SARS-CoV-2 N protein in diagnosis and vaccination in the context of emerging variants: present status and prospects.

作者信息

Song Wanchen, Fang Zhongbiao, Ma Feike, Li Jiaxuan, Huang Zhiwei, Zhang Yanjun, Li Jianhua, Chen Keda

机构信息

School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.

Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.

出版信息

Front Microbiol. 2023 Aug 14;14:1217567. doi: 10.3389/fmicb.2023.1217567. eCollection 2023.

DOI:10.3389/fmicb.2023.1217567
PMID:37675423
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10478715/
Abstract

Despite many countries rapidly revising their strategies to prevent contagions, the number of people infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to surge. The emergent variants that can evade the immune response significantly affect the effectiveness of mainstream vaccines and diagnostic products based on the original spike protein. Therefore, it is essential to focus on the highly conserved nature of the nucleocapsid protein as a potential target in the field of vaccines and diagnostics. In this regard, our review initially discusses the structure, function, and mechanism of action of N protein. Based on this discussion, we summarize the relevant research on the in-depth development and application of diagnostic methods and vaccines based on N protein, such as serology and nucleic acid detection. Such valuable information can aid in designing more efficient diagnostic and vaccine tools that could help end the SARS-CoV-2 pandemic.

摘要

尽管许多国家迅速修订其预防传染病的策略,但感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人数仍在激增。能够逃避免疫反应的新出现变种显著影响了基于原始刺突蛋白的主流疫苗和诊断产品的有效性。因此,将核衣壳蛋白的高度保守性质作为疫苗和诊断领域的潜在靶点至关重要。在这方面,我们的综述首先讨论了N蛋白的结构、功能和作用机制。基于此讨论,我们总结了基于N蛋白的诊断方法和疫苗(如血清学和核酸检测)深入开发和应用的相关研究。这些有价值的信息有助于设计更有效的诊断和疫苗工具,从而有助于终结SARS-CoV-2大流行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/0da3c9cd9d89/fmicb-14-1217567-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/a95f95ebf15a/fmicb-14-1217567-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/c14c49d4e5ae/fmicb-14-1217567-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/e442c92e4a58/fmicb-14-1217567-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/7353e0e015b3/fmicb-14-1217567-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/0da3c9cd9d89/fmicb-14-1217567-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/a95f95ebf15a/fmicb-14-1217567-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/c14c49d4e5ae/fmicb-14-1217567-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/e442c92e4a58/fmicb-14-1217567-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/7353e0e015b3/fmicb-14-1217567-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca37/10478715/0da3c9cd9d89/fmicb-14-1217567-g005.jpg

相似文献

1
The role of SARS-CoV-2 N protein in diagnosis and vaccination in the context of emerging variants: present status and prospects.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)核蛋白在新出现变异株背景下的诊断和疫苗接种中的作用:现状与展望
Front Microbiol. 2023 Aug 14;14:1217567. doi: 10.3389/fmicb.2023.1217567. eCollection 2023.
2
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
3
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
4
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.SARS-CoV-2 变异株特异性复制 RNA 疫苗可预防同源关切变异株挑战后的疾病。
Elife. 2022 Feb 22;11:e75537. doi: 10.7554/eLife.75537.
5
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
6
Next-Generation Vaccines Against COVID-19 Variants: Beyond the Spike Protein.针对新冠病毒变异株的新一代疫苗:超越刺突蛋白
Zoonoses. 2023;3(1). doi: 10.15212/zoonoses-2023-0003. Epub 2023 Apr 19.
7
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
8
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体与疫苗效力
Vaccines (Basel). 2022 Oct 19;10(10):1751. doi: 10.3390/vaccines10101751.
9
Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.野生型 SARS-CoV-2 中和抗体的免疫活性会随着时间推移和变异株的不同而降低,但与诊断检测有很好的相关性。
Front Immunol. 2023 Feb 8;14:1055429. doi: 10.3389/fimmu.2023.1055429. eCollection 2023.
10
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.

引用本文的文献

1
Fluorescence dye-conjugated magnetic core-shell silica nanoparticles for enhanced nucleic acid visualization.用于增强核酸可视化的荧光染料共轭磁性核壳二氧化硅纳米颗粒。
RSC Adv. 2025 Jul 11;15(30):24289-24303. doi: 10.1039/d5ra01931a. eCollection 2025 Jul 10.
2
A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting.同源和异源BNT162b2加强免疫后针对SARS-CoV-2变异株的中和抗体和IgG抗体水平的22个月前瞻性评估。
Sci Rep. 2025 Jul 1;15(1):21175. doi: 10.1038/s41598-025-05377-3.
3
Pushing the Limits of Lateral Flow Immunoassay by Digital SERS for the Ultralow Detection of SARS-CoV-2 Virus.

本文引用的文献

1
SARS-CoV-2 rapid antigen test sensitivity and viral load in newly symptomatic hospital employees in Berlin, Germany, December, 2020 to February, 2022: an observational study.2020 年 12 月至 2022 年 2 月期间德国柏林新出现症状的住院员工中 SARS-CoV-2 快速抗原检测的敏感性和病毒载量:一项观察性研究。
Lancet Microbe. 2024 Jun;5(6):e538-e546. doi: 10.1016/S2666-5247(23)00412-3. Epub 2024 May 14.
2
Sensitivity of rapid antigen tests against SARS-CoV-2 Omicron and Delta variants.快速抗原检测对 SARS-CoV-2 奥密克戎和德尔塔变异株的敏感性。
J Clin Microbiol. 2023 Oct 24;61(10):e0013823. doi: 10.1128/jcm.00138-23. Epub 2023 Sep 20.
3
通过数字表面增强拉曼光谱推动侧向流动免疫分析的极限以实现对SARS-CoV-2病毒的超痕量检测
Small Sci. 2024 Aug 10;4(11):2400259. doi: 10.1002/smsc.202400259. eCollection 2024 Nov.
4
Measuring SARS-CoV-2 RNA in Bangkok wastewater treatment plants and estimating infected population after fully opening the country in 2023, Thailand.在泰国曼谷的污水处理厂中检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)RNA,并估算2023年该国全面开放后受感染的人口数量。
Sci Rep. 2025 Mar 20;15(1):9663. doi: 10.1038/s41598-025-94938-7.
5
Immunological assessment of NSFu1: A novel fusion molecule constructed from structural proteins of SARS-CoV-2 for improving COVID-19 antibody detection.NSFu1的免疫学评估:一种由严重急性呼吸综合征冠状病毒2的结构蛋白构建的新型融合分子,用于改进新型冠状病毒肺炎抗体检测。
Arch Microbiol. 2025 Mar 15;207(4):88. doi: 10.1007/s00203-025-04286-3.
6
Immunoassay Detection of SARS-CoV-2 Using Monoclonal Antibody Binding to Viral Nucleocapsid Protein.使用与病毒核衣壳蛋白结合的单克隆抗体进行 SARS-CoV-2 的免疫测定检测
Microb Biotechnol. 2025 Feb;18(2):e70117. doi: 10.1111/1751-7915.70117.
7
Cattle, sheep, and goat humoral immune responses against SARS-CoV-2.牛、羊和山羊针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的体液免疫反应。
Vet Anim Sci. 2024 Nov 6;26:100408. doi: 10.1016/j.vas.2024.100408. eCollection 2024 Dec.
8
Loop-Mediated Isothermal Amplification (LAMP): An Innovative Approach for the Environmental Monitoring of SARS-CoV-2.环介导等温扩增技术(LAMP):一种用于新型冠状病毒环境监测的创新方法。
Pathogens. 2024 Nov 20;13(11):1022. doi: 10.3390/pathogens13111022.
9
Selection and characterization of human scFvs targeting the SARS-CoV-2 nucleocapsid protein isolated from antibody libraries of COVID-19 patients.从 COVID-19 患者的抗体文库中分离出的针对 SARS-CoV-2 核衣壳蛋白的人源 scFvs 的筛选和鉴定。
Sci Rep. 2024 Jul 9;14(1):15864. doi: 10.1038/s41598-024-66558-0.
10
Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2.Prime-2-CoV的药代动力学和环境风险评估,一种基于非复制型Orf病毒的抗SARS-CoV-2疫苗
Vaccines (Basel). 2024 May 2;12(5):492. doi: 10.3390/vaccines12050492.
A review of current effective COVID-19 testing methods and quality control.
当前有效 COVID-19 检测方法及质量控制综述。
Arch Microbiol. 2023 May 17;205(6):239. doi: 10.1007/s00203-023-03579-9.
4
Rapid antigen-based and rapid molecular tests for the detection of SARS-CoV-2: a rapid review with network meta-analysis of diagnostic test accuracy studies.基于抗原的快速检测和快速分子检测用于 SARS-CoV-2 的检测:一项针对诊断检测准确性研究的快速综述与网络荟萃分析。
BMC Med. 2023 Mar 29;21(1):110. doi: 10.1186/s12916-023-02810-0.
5
COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray.基于快速、多重、即时检测的抗体微阵列技术的 COVID-19 诊断和 SARS-CoV-2 株鉴定。
Anal Chem. 2023 Apr 4;95(13):5610-5617. doi: 10.1021/acs.analchem.2c05180. Epub 2023 Mar 24.
6
SARS-CoV-2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design.严重急性呼吸综合征冠状病毒2核衣壳蛋白:生物学功能及其在疾病诊断和疫苗设计中的意义
Rev Med Virol. 2023 May;33(3):e2431. doi: 10.1002/rmv.2431. Epub 2023 Feb 15.
7
Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model.在小鼠模型中评估五种 SARS-CoV-2 变异株的重组核衣壳蛋白的免疫原性和抗原性。
Viruses. 2023 Jan 13;15(1):230. doi: 10.3390/v15010230.
8
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.令人担忧的 SARS-CoV-2 BQ 和 XBB 亚型不断出现的抗体逃逸特性。
Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14.
9
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.预先存在的交叉反应性免疫对 SARS-CoV-2 感染和疫苗反应的影响。
Nat Rev Immunol. 2023 May;23(5):304-316. doi: 10.1038/s41577-022-00809-x. Epub 2022 Dec 20.
10
Variable detection of Omicron-BA.1 and -BA.2 by SARS-CoV-2 rapid antigen tests.奥密克戎 BA.1 和 BA.2 的快速抗原检测的可变检测。
Med Microbiol Immunol. 2023 Feb;212(1):13-23. doi: 10.1007/s00430-022-00752-7. Epub 2022 Nov 12.